Video

Dr. Busaidy on the Association Between THST and Improved Outcomes

Naifa L. Busaidy, MD, associate professor, MD Anderson Cancer Center, discusses the results of a cooperative study that investigated the association between long-term thyroid hormone suppression therapy and improved outcomes in patients.

Naifa L. Busaidy, MD, associate professor, MD Anderson Cancer Center, discusses the results of a cooperative study that investigated the association between long-term thyroid hormone suppression therapy (THST) and improved outcomes in patients with differentiated thyroid cancer (DTC).

Busaidy says the study, which followed 5000 patients, examined if excess thyroid hormone can improve disease-free survival. It is known that in thyroid cancer, giving a patient excess thyroid hormone will decrease recurrence risk but physicians do not know how much hormone thyroid suppression is most effective.

The study found that thyroid hormone suppression is important for the first 3 years but suppressing the patient beyond 3 years might not be necessary. Busaidy says the study also showed that physicians do not need to aggressively use THST. Suppressing the thyroid hormone can cause adverse events, such as irregular heartbeat and osteoporosis.

Busaidy says it is important to weigh the risks and benefits of each patient.

<<<

View more from the 2014 ATA Annual Meeting

Related Videos
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.
Toni K. Choueiri, MD
Neil J. Shah, MBBS
Ranee Mehra, MD, professor, medicine, medical oncology; director, Head and Neck Medical Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical System
Lori Wirth, MD
Lori Wirth, MD
Marshall Posner, MD
Lori Wirth, MD